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Uveal malignant melanoma (UMM) is a rare malignant adult
neoplasm (incidence: 1/1 000 000), but it is the most common
intraocular primary malignancy. UMM can occur in a familial
setting (reviewed in Canning and Hungerford, 1988). Large
studies have statistically demonstrated an excess of UMM risk in
relatives of UMM patients (Singh et al, 1996b) and it is now
assumed that at least 0.6% of all uveal melanoma cases are
familial (Singh et al, 1996a). Moreover, observation of large pedi-
grees has shown that transmission was autosomal dominant with
incomplete penetrance (Lynch et al, 1968), and that bilateral uveal
melanoma occurred more frequently than expected (Singh et al,
1996e). Numerous clinical and biological data suggest common
hereditary factors for UMM and cutaneous melanoma (CMM).
UMM may occur in familial CMM probands (Newton Bishop et
al, 1994; Van Hees et al, 1998). CMM may be present in 
first-degree relatives of UMM patients, often in association with
dysplastic naevus syndrome (DNS) (Van Hees et al, 1998). 
Co-existence of UMM and CMM in a same individual occur in up
to 2% of UMM patients (Bataille et al, 1993; Van Hees et al,
1998). Finally, uveal and cutaneous melanocytes share a common
embryology, originating in the neural crest. Both cells migrate to
their respective site during embryological development, and may
give rise to naevi and in some instances, to melanomas.
Some other clinical conditions seem to predispose to UMM:
ocular melanocytosis, neurofibromatosis type I, and Li–Fraumeni
syndrome (Singh et al, 1996e). At a genetic level, BRCA2
germline mutations may be associated with an increased risk of
UMM (Easton et al, 1997; Sinilnikova et al, 1999).
Inactivating germline mutations of the p16INK4A gene have been
found to segregate with the disease in 15–50% of CMM families
(familial atypical mole and melanoma syndrome (FAMMM)
(reviewed in Dracopoli and Fountain, 1996). The INK4A-ARF
locus localized at 9p21 encodes two alternative reading frame
proteins, P16INK4A (exons 1a, 2 and 3) and P14ARF (exons 1b, 2 and
3), both involved in the negative control of cell proliferation.
P16INK4A produces a G1 cell cycle arrest by inhibiting phosphoryla-
tion of the retinoblastoma protein by the cyclin-dependent kinases
cdk4 and cdk6 (Serrano et al, 1993). P14ARF is a structurally
different protein, which has been recently shown to act both at G1/S
and G2/M phases, in a p53-dependent manner. This is done via
binding and inhibition of the protein MDM2, which itself promotes
P53 degradation (Stott et al, 1998). In addition, its murine homo-
logue, P19ARF, can directly associate with P53 (Kamijo et al, 1998).
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Summary In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through
inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene
(CDK4). Uveal malignant melanoma (UMM) also occurs in a familial setting, or sometimes in association with familial or sporadic CMM.
Molecular studies of sporadic UMM have revealed somatic deletions covering the INK4A-ARF locus (encoding P16INK4A and P14ARF) in a large
proportion of tumours. We hypothesized that germline mutations in the p16INK4A, p14ARF or CDK4 genes might contribute to some cases of
familial UMM, or to some cases of UMM associated with another melanoma. Out of 155 patients treated at the Institut Curie for UMM between
1994 and 1997, and interviewed about their personal and familial history of melanoma, we identified seven patients with a relative affected
with UMM (n = 6) or CMM (n = 1), and two patients who have had, in addition to UMM, a personal history of second melanoma, UMM (n = 1),
or CMM (n = 1). We screened by polymerase chain reaction single-strand conformation polymorphism the entire coding sequence of the
INK4A-ARF locus (exon 1a from p16INK4A, exon 1b from p14ARF, and exons 2 and 3, common to both genes), as well as the exons 2, 5 and 8
of the CDK4 gene, coding for the functional domains involved in p16 and/or cyclin D1 binding. A previously reported polymorphism in exon 3
of the INK4A-ARF locus was found in one patient affected with bilateral UMM, but no germline mutations were detected, either in the p16INK4A,
p14ARF or CDK4 genes. Our data support the involvement of other genes in predisposition to uveal melanoma. © 2000 Cancer Research
Campaign
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DOI: 10.1054/ bjoc.1999.1005, available online at http://www.idealibrary.com on A second melanoma-susceptibility gene, CDK4, was also
recently characterized. Two different mutations, both occurring at
codon 24 in exon 2 of the gene, were identified in three families,
two American and one French (Zuo et al, 1996, Soufir et al, 1998).
These mutations were shown to segregate in these CMM families
and to prevent P16INK4A binding (Zuo et al, 1996).
Several arguments support that these two genes may play a role
in predisposition to UMM. First, UMM cases were present in
melanoma families that have been linked to the 9p21 locus
(Cannon-Albright et al, 1992). Second, somatic deletions, loss of
heterozygosity of 9p21 genetic markers or 5¢CpG island methyla-
tion of p16INK4A have been detected in UMM cell lines and primary
sporadic UMM (Ohta et al, 1994; Speicher et al, 1994; Merbs et al,
1999). Third, a loss of P16INK4A-cdk4 proteins interaction was
observed in UMM cell lines (Mouriaux et al., 1998). This led us to
search for germline mutations in the entire coding sequence of the
INK4A-ARF locus (exon 1a, exon 1b, exon 2 and 3) and CDK4
(exons 2, 5 and 8) in individuals either with a familial history of
UMM or with a personal history of melanoma, in addition to
UMM.
PATIENTS AND METHODS
Families and patients selection
One hundred and fifty-five individuals (56% female, 44% male)
affected with uveal melanoma and followed at the Institut Curie
between January 1994 and September 1997 were interviewed
about their personal and familial history of melanoma. Patients
with at least an uveal or cutaneous melanoma in a first- to third-
degree relative, or with a personal history of second uveal or cuta-
neous melanoma were proposed for genetic interview. Further
information on family members was therefore collected, including
age at diagnoses, site of melanoma tumours and occurrence 
of other malignancies in affected family members. Diagnosis 
were based on ocular fundus examination, ultrasound and angio-
graphy, and cases treated by enucleation were confirmed by
histopathology. Clinical examination of the skin in index cases
looked for a dysplastic naevus syndrome (defined by more than 
50 naevi, with at least one atypical mole). A blood sample was
obtained by venipuncture, with their informed consent.
Molecular analysis
Genomic DNA was prepared from peripheral blood mononuclear
cells isolated by centrifugation through a Ficoll gradient. Each of
the four exons of the INK4A-ARF locus and the intron–exon junc-
tions were analysed by polymerase chain reaction single-strand
conformation polymorphism (PCR-SSCP). Primer sequences for
the exons 1a, 2, and 3 of the INK4A-ARF locus were described in
Soufir et al (1998). Exon 1b was analysed through two overlap-
ping PCR products generated by using the following primers:
p19F1 5¢-TCAGGGAAGGGCGGGTGCG-3¢, P19R1 5¢-GCC-
GCGGGATGTGAACCA-3¢ (PCR product: 245 bp), p19F2 5¢-
GCCGCGAGTGAGGGTTTT-3¢, p19R2 5¢-CACCGCGGTTAT-
CTCCTC-3¢ (PCR product 257 bp).
Functional and mutational studies of CDK4 gene have focused
on the regions involved in P16INK4A binding, particularly in
domains encompassing the first 58 N-terminal aminoacids or the
C-terminal region (Zuo et al, 1996; Coleman et al, 1997; Byeon 
et al, 1998) and corresponding to exons 2, 5 and 8 of the gene.
These three exons were amplified using flanking intronic primers: 
(i) exon 2 CDK4F2 5¢-AGCGACTTTTGGTGATAGGAGT-3¢,
CDK4R2 5¢-GGCTGTCTTTTCCCTTTACTC-3¢ (PCR product:
322 bp), (ii) exon 5, CDK4F5 5¢-AGAGTGATTGCCCGTAGC-3¢,
CDK4R5 5¢-GCAAGGTATGGATGTGGT-3¢ (PCR product: 296
bp), and (iii) exon 8, CDK4F8 5¢-GCTCATCCCAGGTATTGT-3¢,
CDK4R8 5¢-TTGCCCTCTCAGTGTCCA-3¢ (PCR product: 234
bp). Total PCR reactions volume was 20 ml including 50–100 ng
of genomic DNA template, 30 pmol of each primer, 0.5 UI of Taq
polymerase (Gibco-BRL) and 0.1 ml of a33P-dCTP (Amersham).
Final magnesium chloride (MgCl2) concentration was 1.5 mM for
all PCR reactions. All reactions were supplemented with 10%
dimethyl sulphoxide (DMSO) for optimal PCR amplification.
PCR was processed with an annealing temperature of 60°C for 
the four exons of the INK4A-ARF locus, and 55°C for the 
three studied exons of CDK4. For SSCP, all PCR products 
were migrated on two 0.1 ´ TBE/Hydrolink MDE gels (FMC
Bioproducts), with 8% glycerol at room temperature (RT) and
without glycerol at +4°C. Gels were run at 8W, either 14 h at RT or
12 h at 4°C, dried and exposed for autoradiography. Sample
containing  p16INK4A exon 3 variant migrating band was sequenced
on both strands by automated sequencing using the primers
mentioned above. Products from 50-ml PCR reactions were puri-
fied using a Microcon 100 (Amicon) and sequenced using dye-
labelled terminator on an automated sequencer 373 (Applied
Biosystem) according to the manufacturer’s instructions.
RESULTS
Clinical data
Among the 155 patients with UMM, nine patients (5.8%) were
selected for genetic analysis (Table 1). Nineteen out of 20
melanoma cases (95%) could be confirmed from medical records.
Seven patients had one relative affected with UMM (families 1–4,
6 and 7) or CMM (family 5). In three families, the affected cases
were first-degree related (families 1–3); in two, they were second-
degree related (families 4 and 5), and in the last two, they were
third-degree related (families 6 and 7). In the families 3 and 7, the
affected relative had, in addition to UMM, a CMM. Besides these
seven familial cases, two patients reported a history of second
primary melanoma (families 8 and 9). One had a bilateral UMM
(family 8) and the other, a CMM (family 9). Median age at diag-
nosis was 56 years old (41–80), and sex ratio, three women for one
man. Only one proband (family 9) had a typical dysplastic naevus
syndrome, with numerous atypical moles. In three families,
different malignancies were also present, all confirmed from
medical records (Table 1). In family 3, a prolactin adenoma was
observed in both affected relatives, in addition to UMM. In family
5, a bilateral breast cancer was present in the index case, as well as
a colon cancer and an ovary cancer in the affected relative. In
family 9, the index case had in addition a basal cell carcinoma.
Molecular analysis
Each proband was screened by PCR-SSCP for germline mutation
of the INK4A-ARF locus. No abnormal pattern was detected
either in exon 1a or in exon 2. One abnormal migrating pattern
was observed in exon 3 in one out of nine samples (family 8),
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position 500 (nucleotide numbering beginning at the first ATG
site), located in the p16INK4A cDNA 3¢ untranslated region
(Chaubert et al, 1996). In addition, no sequence variant in exon 1b
of the p14ARF gene was detected in any of the samples, therefore
suggesting that germline mutations in the INK4A-ARF locus are
not a common event in genetic predisposition to UMM. SSCP
analysis of the functional domains of the CDK4 gene did not
reveal any SSCP variants in the nine samples.
DISCUSSION
We have investigated nine white French families that had a highly
suspected UMM predisposition, owing to a personal or familial
history of multiple melanomas. Approximately 1% of patients
affected with UMM report a first- to third-degree relative affected
with the same disease (Singh et al, 1996a). The higher frequency
of familial cases observed in our study (3.9%), as compared with
previous reports, may reflect (i) sampling variation, or (ii) a slight
bias towards the ascertainment of familial cases due to the avail-
ability of genetic counselling consultation at the Institut Curie.
Nevertheless, our data confirm the association between UMM and
CMM, either in relatives of UMM cases, or in the same individ-
uals (families 3, 5, 7 and 9) as previously reported (Bataille et al,
1993).
We did not detect any mutation in the coding sequence of either
the INK4A-ARF locus or CDK4 gene in the nine families studied.
We cannot rule out misdetection of mutations by SSCP, but this
seems unlikely, as we recently reported one of the highest rates of
p16INK4A germline mutation in CMM families, using the same tech-
nical approaches (Soufir et al, 1998). Our data enhance results 
of two previous studies: Wang et al did not find any pathogenic
mutation in 13 UMM patients with a family history of melanoma,
either uveal (n = 6), or cutaneous (n = 7) (Wang et al, 1996); Singh
et al did not detect either any mutation in eight families with two
members affected with UMM (Singh et al 1996c). All 30 UMM
families studied worldwide up to now have in common an absence
of mutation in p16INK4A, therefore supporting the rare involvement
of this gene in genetic predisposition to UMM.
A single nucleotide substitution (G to C) was detected in the 3¢
untranslated region of exon 3 of p16INK4A, in one out of nine
patients (11%), affected with bilateral UMM (family 8). This
nucleotide variant has been previously assessed as being a silent
polymorphism with a maximum frequency of 25% in a European
white population (Chaubert et al, 1996), and of 29% in a set of
sporadic CMM (Kumar et al, 1998). However, more recently,
Aitken et al reported that in CMM prone-families from
Queensland, this polymorphism might be overrepresented as
compared to a healthy population and could therefore have a dele-
terious effect (Aitken et al, 1999). This seems unlikely in UMM
given the low frequency of this variant in our series of nine
patients.
Liu et al recently reported a germ-line transversion GÕT at base
–34 of p16INK4A (in the 5¢ UTR), creating an aberrant initiation
codon, in two CMM families (Liu et al, 1999). In our study, we
detected no mutation up to 104 bp upstream of the first translation
site. Nonetheless, we cannot rule out mutations in the promoter or
other regulatory region of p16INK4A. We did not detect any germline
mutation in exon 1b from p14ARF in our set of families, which
supports that this gene is not involved in predisposition to UMM.
Yet, it should be pointed out that large hemizygous deletions of the
INK4A-ARF locus may have escaped our mutation detection
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Table 1 Patients with a family or personal history of uveal melanoma: characteristics of index cases and affected family members selected for
this study
Selected cases Sex Tumour type Age at Affected Other primary DNS
diagnosis relatives malignancy
Family 1
Index case F UMM 43 * *
Affected relative M UMM 62 Father *
Family 2
Index case F UMM 62 * *
Affected relative M UMM 80 Father *
Family 3
Index case F UMM 70 Prolactinoma (60) *
Affected relative F UMM, CMM 44, 63 Sister Prolactinoma (59)
Family 4
Index case F UMM 48 * *
Affected relative F UMM 49 Maternal aunt *
Family 5
Index case F UMM 69 Bilateral breast K (52, 53) *
Affected relative F CMM 42 Niece Colon K (42), ovary K (43)
Family 6
Index case F UMM 33 * *
Affected relative M UMM 42 Paternal cousin *
Family 7
Index case F UMM 69 * *
Affected relative M UMM, CMM 67, 63 Maternal cousin *
Family 8
Index case F Bilateral UMM 69, 69 * * *
Family 9
Index case F UMM, CMM 41, 44 * Basal cell carcinoma (40) yes
DNS, dysplastic naevus syndrome. In bold letters, cases whose diagnosis was confirmed by medical records.strategy. However, such genomic rearrangements seem rather to
predispose to melanoma-astrocytoma syndrome (Bahuau et al,
1998).
We did not find any germline mutation in CDK4 gene. Thus,
despite the fact that our series is small and CDK4 is less frequently
involved in familial CMM than p16INK4A, CDK4 gene does not
seem to play a major role in genetic predisposition to UMM. This
conclusion is consistent with previous data reporting the absence
of somatic mutation of this gene in 30 primary uveal melanomas
(Tsao et al, 1998). However, to rule out definitively CDK4 as a
UMM predisposing gene, further studies should be performed on
larger family sets.
Genes other than p16INK4A, p14ARF and CDK4 might be involved
in predisposition to UMM. First, involvement of another gene
localized within the 9p21 locus is supported by (i) the occurrence
of somatic deletions of 9p21 markers in up to 30% of UMM
tumours (Otah et al, 1994), (ii) the presence of homozygous
somatic deletions sparing the INK4A-ARF locus in CMM tumours
(Puig et al, 1995), and (iii) the absence of p16INK4A germline muta-
tion in cutaneous melanoma kindreds linked to 9p21 locus (Kamb
et al, 1994; Liu et al, 1997). Second, a third melanoma suscepti-
bility locus at 1p36 was initially characterized for the combined
melanoma/dysplastic naevus trait (Bale et al, 1989; Goldstein et al,
1993). As UMM and CMM may be genetically related via the
sporadic DNS or the FAMMM syndrome (Bataille et al, 1993;
Singh et al, 1996c; Van Hees et al, 1998), this locus might be
involved in genetic predisposition to UMM. Third, BRCA2
germline mutations might account for some UMM cases associ-
ated with a personal history of breast cancer (Sinilnikova et al,
1999). However, in family 7, no germline BRCA2 mutation was
detected despite the strong suggestion for the involvement of this
gene (Table 1) (Sinilnikova et al, 1999).
Finally, loss of heterozygosity and cytogenetic studies have
suggested that tumour suppressor genes on chromosomes 2, 3 and
6, as well as an oncogene on chromosome 8q, could be involved in
the tumorigenic process of uveal tumours (Prescher et al, 1994).
In conclusion, our results suggest that germline mutations of
p16INK4A, p14ARF and CDK4 genes are not frequently observed in
genetic predisposition to UMM. This confirms genetic hetero-
geneity, therefore supporting the existence of additional melanoma
susceptibility genes.
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